A2 (à¬34H46N2Q17S), paulomycin C (C32H42N2Qi7S), paulomycin D (C3iH4oN2Oi7S), paulomycin E (C29H36N2O16S) and paulomycin F (C29H38N2O16S) have been isolated from fermentations of Streptomyces paulus strain 273. The structure of these compounds was determined using NMRand mass spectroscopic techniques. The new paulomycins, like paulomycins A and B (J. Antibiotics 35: 285~294, 1982) are highly active mainly against Gram-positive organisms.
The production of the paulomycin complex by Streptomyces paulus strain 273 and the isolation and separation of paulornycins Aand B, the main components of the mixture, were reported by Argoudelis and his co-workers.1} This paper describes the isolation, characterization and structure of several bioactive minor components produced by 8. paulus. The biological properties of these new paulomycins, designated paulomycins A2, C, D, E and F are also briefly discussed.
Exp er imenta l
Assay and Testing ProceduresAntibiotic production and purification was measured by a microbiological disc-plate assay procedure with Microcoecus luteus as the assay organism.
TLC Procedures The production of paulomycins' was followed by TLCon Silica gel G using chloroform -ethanolwater (25 : 30 : 5) or chloroform -MeOH(90 : 10) as the solvent system. Paulomycins were separated by TLCusing Brinkman's cellulose-coated plates and pH 7.0 phosphate buffer as the solvent system. The antibiotics were detected by bioautography on M. luteus seeded trays.
Spectroscopic Methods UVspectra were obtained in MeOHusing a Perkin-Elmer Lambda 7 spectrophotometer, IR spectra, were run in Nujol mull using a Digilab FTS-ISE spectrometer. 1H NMRspectra were recorded on a Varian XL-200 spectrometer operating at 200 MHz.Solutions (ca. 0.4 ml, ca. 0.25 m) of the compoundsin deuterated chloroform or acetone were used. 13C NMR spectra were recorded on a Varian CFT-20 spectrometer operating at 20.0 MHz.XHand 13C NMRchemical shifts are reported as ppm relative to TMS.Negative ion MSwere obtained on a V.G. Analytical ZAB-2Fhigh resolution mass spectrometer using a fast atom bombardment(FAB) source. Bombarding gas, xenon, ac- 
Fermentation Conditions
The fermentation conditions, used for the production of the paulomycin complex by S. paulus strain 273 (UC 5142), were identical to those described by Marshall et aL2) Amberlite XAD-2 resin (150 liters per 5,000 liters fermentation) was added into the fermentor. Bioassays indicated that at harvest time (120 hours after inoculation) most of the bioactive components produced by S. paulus were adsorbed on the resin.
Isolation of Antibiotics Produced by S. paulus Extraction with Ethyl Acetate, Isolation of Crude Crystals of Paulomycins The fermentation broth (ca. 5,000 liters) was adjusted to pH 4.5 with aqueous sulfuric acid and then passed over a large vibrating screen in order to remove the Amberlite XAD-2resin. The resin was slurried in 100 liters of water and screened off on the vibrating screen. The washed resin was packed in a column, washed with 100 liters of cyclohexane -methylene chloride (4 : 1) mixture and then eluted with 1,400 liters of ethyl acetate. The ethyl acetate eluate was concentrated to dryness. The residue was triturated twice with /z-heptane and then crystallized from methylene chloride. The crude crystalline preparation obtained (625 g) was dissolved in 3.2 liters of ethyl acetate. The solution was mixed with 31 g of filter aid and 31 g of Darco G-60 and stirred for 1 hour. The mixture was then filtered over filter aid and the filtrate was mixed with 3.2 liters of /z-hexane. The cloudy solution, stored at 5°C for 24 hours, yielded 386 g of crystalline needles. This material was found by HPLC to be a mixture of paulomycins A and B. The mother liquors concentrated to dryness yielded ca. 200 g of material enriched in bioactive components other than paulomycins A and B. This material was used for the isolation of paulomycins A2, C, D, E and F as discussed below.
Isolation of Paulomycin A2, Partition Chromatography Six hundred g of Dicalite 4200 was slurried with 2,800 ml of upper phase and 200 ml of lower phase of the solvent system consisting of dioxane -cyclohexane -0.1 mphosphate buffer (pH 7.0) (35 : 68 : 8). The slurry was then poured into a column and packed to a constant height. The starting material, 3.0 g of the crude mixture of paulomycins obtained as described above, was dissolved in 15 ml of lower phase and 10 ml of upper phase, mixed with 15 g of Dicalite and added on the top ofthecolumn. The column was eluted with the upper phase. Eluate fractions containing, by HPLC,paulomycin A2 were combined and concentrated to dryness to yield 40 mg of crystalline paulomycin A2 which was recrystallized from chloroform -ether. Characterization of this material is described later in this manuscript.
Separation of "Polar Paulomycins"1 from Paulomycins A, A2 and B, Preparative HPLC Two Waters C-18 reverse phase silica packed columns, attached to a Waters Prep 500A instrument, were equilibrated with the mobile phase consisting of acetonitrile -0.01 m phosphate buffer (pH 5.5) (1 : 1). Forty g of the crude paulomycin, isolated as described above, was dissolved in 400 ml of the mobile phase and the solution was injected into the first column of the system. The chromatography was run with a flow rate of 100 ml/minute using the above mobile system and followed by a UVdetector operating at 275 and 320 nm. In addition, selected fractions were analyzed by TLC using KC-18 reverse phase silica plates and acetonitrile -MeOH-0.01 m phosphate buffer (pH 5.5) (1 : 1 : 1) as the mobile phase. Fractions containing the "polar paulomycins" were combined and the solution was extracted twice with 50%of its volume of methylene chloride. The methylene chloride extracts were concentrated to dryness to give 9.0 g of material containing "polar paulomycins" only. A total of 108 g of a mixture of "polar paulomycins" was obtained from purification of 480 g * The term "polar paulomycins" has been used to designate collectively all the new paulomycins and paulomycin-related metabolites with HPLCretention times (RT) lower than the RT of paulomycin B. Paulomycin A2, which has RT higher than that of paulomycin B, is not included in this group.
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of the crude paulomycin mixture. Separation of "Polar Paulomycins", Preparative HPLC The conditions used were identical to those described above with the exception that the mobile phase consisted of acetonitrile -0.01 m phosphate buffer (pH 5.5) (45 : 55). The starting material, 10.0 g of the mixture of "polar paulomycins" obtained as described above was dissolved in 400 ml of the mobile phase and injected into the first column of the system. Collected fractions, analyzed by UV and analytical HPLC, were treated as follows. Four pools were madefrom fractions containing materials with retention times similar to those of paulomycins C, D, E, and F, respectively.
Each pool was extracted with 15% of its volume of methylene chloride. The extracts, dried over sodium sulfate, were concentrated to dryness. A total of 10 runs were made using conditions identical to those discussed above. Purified paulomycin C, 13.5 g; paulomycin D, 38.1 g; paulomycin E, 28.8 g; and paulomycin F, 4.98 g were obtained by combination of the appropriate preparations.
Isolation of Pure Paulomycins C, D, E, and F, Preparative HPLC Purified paulomycins C, D, E and F were used as the starting materials in preparative HPLC's using conditions identical to those described earlier with the exception that the following mobile phases . Fractions obtained during the chromatographies were examined by analytical HPLC,UVand bioactivity. Appropriate pools were made and these solutions were extracted with 15~20%of their volume of methylene chloride. The extracts were dried over sodium sulfate and concentrated to dryness. The residues were dissolved in acetone and the solutions were mixed with cyclohexane.
Precipitated pure paulomycins C, D, E and F were isolated by filtration and dried. Characterization of these materials is described in the next section (Results and Discussion).
Results and Discussion
As reported earlier,0 S. paulus strain 273 produces paulomycin, a mixture of chemically related antibiotics, whengrown either on agar or in a submerged culture. The isolation of the paulomycin mixture was followed with bioassays and TLCon silica gel plates using chloroform -ethanol -water (25 : 30 : 5) as the mobile phase. The paulomycin complex appeared as one zone of bioactivity (Rf 0.8) when TLCwere developed by bioautography on M. luteus. However, the paulomycin components were separated by TLCon cellulose sheets. Six zones of bioactivity were detected and designated as paulomycin A (Rf 0.14), paulomycin B (Rf 0.32), paulomycin C (Rf 0.43), paulomycin D (Rf 0.58), paulomycin E (Rf 0.77) and paulomycin F (Rf 0.88) (Fig. 1) . Paulomycin A2 could not be separated from paulomycin A in this TLCsystem. However, all paulomycins A, A2, B, C, D, E and F could be separated by analytical HPLC. Detection at 320 nm gave excellent sensitivity for the various paulomycins while reducing to a minimumthe appearance of interfering sub- stances. An HPLC separation ofpaulomycins A, A2, B, C, D, E and F is shown in Fig. 2 .
Isolation of Paulomycins
Fermentations of $. paulus were run in the presence of Amberlite XAD-2.Under these conditions, most of the paulomycins produced were adsorbed on the resin which, at harvest time, was separated from the mycelia by passing over a large vibrating screen. Paulomycins A, A2, B, C, D, E and F were eluted from the resin by ethyl acetate which was concentrated to dryness. The residue was triturated with /z-heptane then crystallized from methylene chloride. The crude crystals were recrystallized from ethyl acetate -/i-hexane to yield a crystalline mixture of paulomycins A and B. The mother liquors, concentrated to dryness, yielded material enriched in paulomycins A2, C, D, E andF.
Pure paulomycin A2 was obtained by partition chromatography on Dicalite 4200 using dioxanecyclohexane -0.1 m phosphate buffer (pH 7.0) as the mobile phase. Pure paulomycins C, D, E and F were obtained by repeated preparative HPLC's using a Waters 500A preparative system and Waters C-18 reverse phase silica columns. The mobile phases varied depending on the nature of the paulomycin under purification. These separations are detailed in the Experimental part of this manuscript. antibiotics melt with decomposition over a broad range of temperature; they are dextrorotatory whenthe specific rotation was determined in chloroform and levorotatory when methanol was used as the solvent. The molecular formulas and molecular weights were determined by negative Table 2 . The XH NMRspectra of paulomycins A2, C, D, E and F are similar to those of paulomycins A and B.1} Table 3 presents selected absorptions, observed in the XH NMRspectra of paulomycins A, A2, B, C, D, E and F due to basic features of these antibiotics. All paulomycins (A, A2, B, C, D, E and F) gave negative ion FAB-MSwhich were almost identical at the low mass (below m/z 360) area of the spectra. Table 4 presents major ions which are commonto all paulomycins. These ions, obtained by fragmentation of paulomycins A and B were mass measured to ions of the matrix (tetraethylene glycol). Structural assignments to these ions are presented in Fig. 7 . Intense molecular ion peaks and peaks corresponding to M-18 were observed in the negative ion FAB-MSof all paulomycins. The molecular ion peak is often one of the mostabundant ions in the spectrum. Thus a simple inspection of the molecular ion region often reveals the purity of a given preparation and this allows a rapid detection of the impurity present. In the case of a mixture of paulomycins, i.e. paulomycins A and B, it allows us to determine the proportion of each of the components in a given lot by measuring the abundances of the molecular ions (M~) at m\z 772 and 786. An example of a spectrum of such a mixture is shown in Fig. 5 . Here the abundances of the two molecular ions were m/z 84.1 and 59.6. Thus the ratio of paulomycin A to B is 1.41. Such ratios were determined for several samples and showed surprisingly good agreement with liquid chromatographic determinations.
The Structure of Paulomycins A2, C, D, E and F The structures of paulomycins A and B have been reported by Wiley and his co-workers3) and are shown in Fig. 6 . The nucleus of the paulomycin molecule consists of two ring systems designated A and B. The maximumat 320 nmin the UVspectra of paulomycins arise from the chromophoric c-r system in ring A. Any structural change in ring A like dehydration of the tertiary hydroxyl at C-6 or reduction of the ketonic functions at C-4 and/or C-7 results in loss of the 320 nmUVmaximum. Ring B is a poly-substituted tetrahydropyrane system. An eight carbon branched sugar, namedpaulomycose, is linked glycosidically to the C-10 hydroxyl group of ring B. This sugar which contains a methoxy group is esterified by 2-methylbutyric acid in paulomycin A and by isobutyric acid in paulomycin B. An a,^8-unsaturated acid moiety is esterified to the hydroxyl at C-ll of ring B. This acid, namedpaulic acid, contains an isothiocyanate group which is the most characteristic chemical feature of paulomycins A and B and is responsible for the intense IR absorption at 2043 cm"1. The unsaturated system of paulic acid is responsible for the UVmaximumat 276 nm. Removal of this moiety from paulomycin A or B results in the formation of paulomenol A or B3) which do not show UV £ Table 3 .^NMRchemical shifts of selected groups ofpaulomycins A, A2, B, C, D, E and F. (Tables 2 and 3 ) support this conclusion. Furthermore, MS data (Table 4 and Fig. 7 ) indicate that all paulomycins (A, A2, B, C, D, E and F) have identical fragmentation patterns at the low mass area {mjz <360) indicating that moiety 8 is a commonstructural feature of all paulomycins.
The structural differences between paulomycins are located in the esterified paulomycose part of the paulomycin molecule. Paulomycin A2 has a molecular composition (Table 1) identical to that ofpaulomycin A. 13C NMRspectra (Table 2) indicate that both antibiotics contain paulomycose esterified to a five carbon acid which in the case of paulomycin A (1) is 2- >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64 In vitro antibacterial data were provided by Mr. G. E. Zurenko and B. H. Yagi of The Upjohn Company. Test method: Agar dilution, pH 6.0.
